Protagonist Therapeutics, Inc. PTGX 深 沪
等待开盘 06-26 09:30:00 美东时间
122.67
+0.520
+0.43%
华盛通- 最 高126.19
- 今 开122.31
- 成交量 90.15万股
- 最 低 113.24
- 昨 收 122.15
- 总市值 596.87万
- 52周最高 126.19
- 市盈率 静 --
- 换手率 1852.86%
- 52周最低 49.39
- 委 比 -98.85%
- 总股本 4.87万
- 历史最高 126.19
- 量 比 1.01
- 振 幅 10.60%
- 历史最低 1.10
- 每 手 1
- 风险率 17.98%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多This $300 Million Biotech May Be Deeply Mispriced: Analyst
Silence Therapeutics ($SLN) stock surges as Cantor predicts key August Phase 2 data will be a major catalyst in the PV market.
06-25 02:22
AbbVie Expands Immunology Footprint With Apogee $11 Billion Acquisition
AbbVie will acquire Apogee for $10.9 billion, adding late-stage immunology and asthma assets to its pipeline.
06-22 21:15
Silence Therapeutics Stock Rises On Positive Blood Cancer Drug Data
Silence Therapeutics says SANRECO data show sustained polycythemia vera benefits as analysts weigh divesiran's profile against rusfertide.
06-12 22:47
BTIG Reiterates Buy on Protagonist Therapeutics, Maintains $82 Price Target
BTIG analyst Julian Harrison reiterates Protagonist Therapeutics (NASDAQ:PTGX) with a Buy and maintains $82 price target.
2025-10-28 17:23
每日全球并购：康为世纪拟收购昊为泰49%股权 | 立桥证券控股完成收购海山股份（10/14）
-每日资讯- 1、康为世纪收购昊为泰少数股东股权并完成全资控股 江苏康为世纪生物科技股份有限公司拟以1,788.50万元收购控股子公司上海昊为泰生物科技有限公...
2025-10-14 20:42
华鑫证券-医药行业周报：外部短期变化，不改长期出海趋势-251012
炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ （来源：研报虎） 1.创新药出海是长期趋势，外部环境变化影响有限 根据医药...
2025-10-12 23:07
口服多肽向FDA递交上市申请 药明康德共同强生等参与
（来源：银柿财经） Icotrokinra是一款潜在“first-in-class”的靶向口服多肽，能够选择性阻断IL-23受体（IL-23R）。 据药明康...
2025-07-22 09:22
Gilead Sciences To Rally Around 11%? Here Are 10 Top Analyst Forecasts For Tuesday
Top Wall Street analysts changed their outlook on these top names. For a comple...
2025-03-11 21:12
Why Is Protagonist Therapeutics Stock Trading Higher On Monday?
Protagonist and Johnson & Johnson's treatment for ulcerative colitis and psoriasis studies met key endpoints.
2025-03-10 22:04
Truist Securities Initiates Coverage On Protagonist Therapeutics with Buy Rating, Announces Price Target of $60
Truist Securities analyst Srikripa Devarakonda initiates coverage on Protagonist Therapeutics (NASDAQ:PTGX) with a Buy rating and announces Price Target of $60.
2024-09-09 21:47
